U.S. market Closed. Opens in 16 hours 51 minutes

CARM | Carisma Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue14.92M9.83M26.54M11.24MN/AN/A
Cost of Revenue8.27M6.09M85.00KN/A219.00KN/A
Gross Profit6.65M3.74M26.46M11.24M-219.00KN/A
Operating Expenses95.39M59.91M40.79M28.38M36.65M25.70M
Selling, General & Admin21.26M3.29M6.41M5.09M12.21M11.62M
Research & Development74.12M56.62M34.39M23.29M24.44M14.08M
Other Operating ExpensesN/AN/AN/AN/AN/AN/A
Operating Income-88.73M-56.16M-40.79M-28.38M-36.87M-33.69M
Other Expenses / Income1.85M-5.06M10.00K29.00K-70.63MN/A
Before Tax Income-86.88M-61.23M-40.78M-28.35M-107.50M-33.69M
Income Tax Expenses8.10M-3.88M-10.00K-29.00KN/AN/A
Net Income-86.88M-61.23M-40.77M-28.32M-107.50M-33.69M
Interest Expenses1.94M3.15MN/AN/AN/AN/A
Basic Shares Outstanding33.52M106.40K9.12M5.91M4.55M3.09M
Diluted Shares Outstanding33.52M106.40K9.12M5.91M4.55M3.09M
EBITDA-80.47M-50.07M-40.11M-27.93M-36.65M-33.48M
EBITDA Margin-539.35%-509.17%-151.12%-248.58%0.00%0.00%
EBIT-76.85M-61.96M-40.78M-28.35M-107.50M-33.69M
EBIT Margin-515.09%-630.02%-153.65%-252.31%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙